China Regulatory Roundup: AZ Gains PD-L1 Green Light Ahead Of Roche
But Can China Take As Many As Eight More?
Oncology continues to dominate new drug approvals in China as AstraZeneca gains the first clearance for a PD-L1 drug ahead of Roche. But there are as many as seven others in the class coming along, including from domestic firms Hengrui and CStone.
You may also be interested in...
Full PACIFIC data show strong overall survival benefit in all comers, though not in a post hoc analysis of those with low PD-L1 expression, about 20% of the population.
A new commissioner has taken the reins at China's National Medical Products Administration, but the senior CCP official has so far given few clear indications about the changes he might bring.
Within a month of obtaining its global first approval in China, Hua Medicine's dorzagliatin is already available in hospitals. What was behind the successful launch of the first-in-class diabetes agent, what are reimbursement plans and how will local commercialization partner Bayer help? Founder and CEO Li Chen sits down to discuss these and other strategies.